Tianjin Lisheng Pharmaceutical Co Ltd (002393) — Cash Flow-to-Debt Ratio
Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Cash Flow-to-Debt Ratio of 0.32x as of December 2025, meaning its operating cash flow of CN¥287.81 Million could theoretically repay 0% of its total liabilities (CN¥890.89 Million) in one year. Explore 002393 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tianjin Lisheng Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2007–2025)
Historical debt coverage capacity for Tianjin Lisheng Pharmaceutical Co Ltd across 19 annual periods. Also explore Tianjin Lisheng Pharmaceutical Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
Year-by-year debt coverage analysis for Tianjin Lisheng Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Tianjin Lisheng Pharmaceutical Co Ltd (002393) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.51x | CN¥451.85 Million | CN¥890.89 Million | ▲ +466.3% |
| 2024 | 0.09x | CN¥88.26 Million | CN¥985.54 Million | ▼ -62.5% |
| 2023 | 0.24x | CN¥209.51 Million | CN¥877.17 Million | ▼ -32.1% |
| 2022 | 0.35x | CN¥331.38 Million | CN¥941.66 Million | ▲ +39.9% |
| 2021 | 0.25x | CN¥196.34 Million | CN¥780.42 Million | ▲ +137.2% |
| 2020 | 0.11x | CN¥76.37 Million | CN¥720.09 Million | ▼ -66.2% |
| 2019 | 0.31x | CN¥268.33 Million | CN¥855.85 Million | ▲ +35.8% |
| 2018 | 0.23x | CN¥162.69 Million | CN¥704.85 Million | ▼ -22.4% |
| 2017 | 0.30x | CN¥179.25 Million | CN¥602.32 Million | ▼ -19.3% |
| 2016 | 0.37x | CN¥173.60 Million | CN¥470.60 Million | ▼ -18.2% |
| 2015 | 0.45x | CN¥198.13 Million | CN¥439.50 Million | ▲ +110.9% |
| 2014 | 0.21x | CN¥72.24 Million | CN¥337.89 Million | ▼ -78.0% |
| 2013 | 0.97x | CN¥289.62 Million | CN¥298.20 Million | ▼ -42.6% |
| 2012 | 1.69x | CN¥250.72 Million | CN¥148.13 Million | ▼ -19.4% |
| 2011 | 2.10x | CN¥134.58 Million | CN¥64.07 Million | ▼ -13.2% |
| 2010 | 2.42x | CN¥186.55 Million | CN¥77.12 Million | ▲ +407.2% |
| 2009 | 0.48x | CN¥196.14 Million | CN¥411.26 Million | ▲ +1.9% |
| 2008 | 0.47x | CN¥126.59 Million | CN¥270.58 Million | ▲ +18.2% |
| 2007 | 0.40x | CN¥174.94 Million | CN¥441.87 Million | — |